Novel platforms for biomedical HIV prevention delivery to key populations—community mobile clinics, peer-supported, pharmacy-led PrEP delivery, and the use of …

E Rousseau, RF Julies, N Madubela… - Current HIV/AIDS …, 2021 - Springer
Purpose of Review A gap exists between PrEP interest and PrEP uptake in key populations
(KP) for HIV prevention that may be ascribed to PrEP delivery services not being acceptable …

Multi-level interventions to promote oral pre-exposure prophylaxis use among adolescent girls and young women: a review of recent research

E Irungu, N Khoza, J Velloza - Current HIV/AIDS Reports, 2021 - Springer
Purpose of review This review summarizes interventions to promote HIV pre-exposure
prophylaxis (PrEP) use among adolescent girls and young women (AGYW) in HIV endemic …

Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women

L Zhang, S Iannuzzi, A Chaturvedula, E Irungu… - Nature medicine, 2023 - nature.com
Most human immunodeficiency virus (HIV) infections occur in cisgender women in resource-
limited settings. In women, self-protection with emtricitabine/tenofovir disoproxil fumarate pre …

[图书][B] Improving antenatal iron-containing supplementation indicators: a report on key informant interviews, an online survey and DHS data analyses

World Health Organization… - 2020 - books.google.com
Page 1 IMPROVING ANTENATAL IRON-CONTAINING SUPPLEMENTATION INDICATORS
REPORT OF KEY INFORMANT INTERVIEWS, ONLINE SURVEY, AND DHS DATA …

PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project

CL Celum, EA Bukusi, LG Bekker… - Journal of the …, 2022 - Wiley Online Library
Introduction HIV incidence remains high among African adolescent girls and young women
(AGYW). The primary objective of this study is to assess pre‐exposure prophylaxis (PrEP) …

Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence

M Moore, S Stansfield, DJ Donnell, MC Boily… - Nature medicine, 2023 - nature.com
Pre-exposure prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate and emtricitabine
administered orally daily is effective in preventing human immunodeficiency virus (HIV) …

Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among …

G Nair, C Celum, D Szydlo, ER Brown, CA Akello… - The Lancet …, 2023 - thelancet.com
Background Half of new HIV acquisitions in Africa occur in adolescent girls and young
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …

Preparing for long‐acting prep delivery: building on lessons from oral prep

C Celum, B Grinsztejn, K Ngure - Journal of the International …, 2023 - Wiley Online Library
Introduction With recent approvals of long‐acting (LA) HIV pre‐exposure prophylaxis (PrEP)
in the form of injectable cabotegravir and the dapivirine ring, programmes need to consider …

HIV prevention: better choice for better coverage

LG Bekker, C Pike, SL Hillier - African Journal of Reproduction …, 2022 - journals.lww.com
Introduction: Antiretroviral-based pre-exposure prophylaxis (PrEP) is today an established,
effective and safe method of HIV prevention used in multiple countries worldwide by a broad …

Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a …

L Jamieson, LF Johnson, BE Nichols… - The Lancet …, 2022 - thelancet.com
Background Long-acting injectable cabotegravir, a drug taken every 2 months, has been
shown to be more effective at preventing HIV infection than daily oral tenofovir disoproxil …